Heart Risks with BRAF and MEK Inhibitor Melanoma Therapies

Recent research highlights the cardiovascular risks associated with BRAF and MEK inhibitor therapies used to treat melanoma. A prospective study published in JACC: CardioOncology found that nearly half of melanoma patients receiving these therapies developed hypertension and/or cancer therapy–related cardiac dysfunction. Understanding these risks and implementing appropriate monitoring strategies are crucial for optimizing patient care.

The Link Between Melanoma Therapies and Heart Health

BRAF and MEK inhibitors work by targeting the MAPK pathway, a regulator of cell growth and survival. While effective in controlling cancer, this pathway also plays a role in cardiac and vascular cell signaling. Manipulating this pathway can lead to unintended cardiovascular effects, though the exact mechanisms are still being investigated.

Key Findings from the Study

• Incidence of Cardiac Issues: 45.9% of patients developed either hypertension or cancer therapy–related cardiac dysfunction.
• Severity of Dysfunction: Most cases of cardiac dysfunction were mild, but moderate or severe cases were observed in a subset of patients.
• Timing of Onset: Moderate or severe cardiac dysfunction typically became evident within the first four weeks of treatment.
• Baseline Risk Matters: Patients with higher baseline cardiotoxicity risk were more likely to experience moderate or severe cardiac dysfunction. No patients classified as low risk developed moderate or severe dysfunction.
• NT-proBNP Levels: Higher baseline levels of NT-proBNP (a biomarker for heart stress) were associated with an increased risk of cardiac dysfunction.

Current Guidelines and Recommendations

Current European Society of Cardiology (ESC) guidelines recommend risk stratification before initiating targeted therapies using the Heart Failure Association (HFA)/International Cardio-Oncology Society (IC-OS) cardiotoxicity risk tool. Routine blood pressure monitoring and electrocardiography are advised, with echocardiographic assessment tailored to baseline risk. However, the study authors note that these recommendations lack robust supporting evidence.

Recommendations for Improved Monitoring

Based on the study findings, researchers suggest the following:

• Early Echocardiographic Assessment: Consider echocardiographic assessment at four weeks for all patients starting BRAF or MEK inhibitors, except those at lowest baseline risk.
• Routine Blood Pressure Monitoring: Regularly assess blood pressure, including home monitoring.
• NT-proBNP Measurement: Utilize NT-proBNP as a potential biomarker for risk stratification.

Future Directions

Further research is needed to refine risk stratification strategies and determine the optimal intensity of cardiac surveillance for patients receiving BRAF or MEK inhibitors. The goal is to allow patients to benefit from effective cancer therapy while minimizing cardiovascular risks.

Key Takeaways

• BRAF and MEK inhibitors can cause cardiovascular side effects, including hypertension and cardiac dysfunction.
• Early detection and management of these side effects are crucial.
• Baseline risk stratification and regular monitoring are essential components of patient care.